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aprotinin package insert provided by the drug's manufac- 
turer. 
The well-designed, randomized, blinded, placebo-con- 
trolled study reported by Vander Salm and associates i  of 
value to cardiac surgeons and anesthesiologists in that it 
provides data regarding the efficacy (or the lack thereof) 
of EACA. As a surgeon who administers EACA on a 
regular basis and aprotinin to selected patients, this 
information is of interest to me. In my opinion, however, 
the authors' conclusions regarding the relative fficacy of 
EACA and their comparisons with aprotinin do not fit the 
results presented and should therefore be carefully con- 
sidered by the reader. 
John H. Lemmer, Jt:, MD 
Northwest Surgical Associates 
2226 N. IV.. Pettygrove 
Portland, OR 97210-2608 
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12/8/80547 
Reply to the Editor." 
As Lemmer points out, correctly, our recent paper 
documented a reduction in chest ube drainage during the 
first 24 hours of about 200 ml after the use of epsilon- 
aminocaproic acid (EACA). 1 In that same series of pa- 
tients, we did not observe a reduction in blood product 
administration. 
We disagree, however, with his characterization f the 
reduction in blood as "essentially negative results." In 
fact. the 200 ml incremental blood loss in the control 
group represents a 30% increase (p = 0.002). One reason 
for the difference of (only) about 200 ml between the 
control and EACA groups is that the patients operated on 
by surgeon 1 in the study had significantly ess bleeding 
than the other patients, and surgeon 1 operated on a 
disproportionately large number of patients in the controI 
group: 65% of the control patients were operated on by 
surgeon 1. and 56% of surgeon l's patients were control 
patients. The second reason is that the overall blood loss 
in the series was low: 647 ml and 839 ml at 24 hours in the 
EACA and control groups, respectively. After reading 
Lemmer's criticisms, we almost feel obliged to apologize 
for our institution's good results. Had we a higher ate of 
blood loss. the difference between the control and EACA 
groups might have been greater, and a significant differ- 
ence in blood product administration might also have 
been observed. 
Except for the comparison of the cost of the two drugs, 
we did not compare EACA with aprotinin. Because 
Lemmer suggests that we drew conclusions regarding the 
relative efficacy of EACA and aprotinin (we did not), it 
may be of some use now to compare the results in our 
recent study with those of the excellent and conclusive 
multiinstitutional study of aprotinin reported by Lemmer 
and colleagues. 2 Our 24-hour cumulative blood losses 
were 647 ml in the EACA group and 839 ml in the control 
group. In Lemmer's report, the blood losses in primary 
coronary artery bypass graft (CABG) cohort at the time of 
chest tube removal were 855 ml and 1503 ml in the 
aprotinin and control groups, respectively. Inasmuch as 
the chest ubes in the Lemmer series were removed earlier 
(20.9 hours and 17.3 hours in the aprotinin and control 
groups, respectively) than in our patients (postoperative 
day 2), the hourly drainage rate in our series (calculated at 
24 hours) is considerably less than in the Lemmer series 
(Table I). In their redo CABG cohort, the losses were 
1225 ml and 1979 ml in the aprotinin and control groups, 
respectively. The results we reported are for all types of 
cardiac operations, including valve operations and redo 
operations. Thus, in this group of patients expected to be 
at higher isk of bleeding than were the patients reported 
on by Lemmer. our control patients had about as much 
bleeding as did the aprotinin-treated patients in Lemmer's 
series, and our treatment (with EACA) patients has less 
bleeding. 
Although our red cell administration rate for the pa- 
tients receivmg EACA was slightly less than for the 
control patients, the difference was not statistically signif- 
icant. Again, comparison with the patients in Lemmer's 
series erves to put the transfusion rates in proper context. 
Our transfusion threshold was a hematocrit value of 25%: 
in Lemmer's eries it was 21%. With a higher hematocrit 
threshold in our series than in Lemmer's. and a study 
group that included complex valve operations as well as 
redo operations, a higher rate of transfusion would be 
expected in our series. Our EACA and control groups had 
a mean of 1.13 units and 1.35 units of packed red cells 
transfused, respectively; inLemmer's eries, the aprotinin 
and control groups had 1.1 and 2.1 units transfused. 
respectively. Our treatment and control groups had blood 
replacement a close to the level of Lemmer's aprotinin- 
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Table I 
Vander Salm series (all patients) Lemmer series (primary CABG) 
Control EA CA Control Aprotinin 
Chest tube drainage rate (ml/hr) 
Chest tube drainage (ml) 
Mean No. units of RBCs transfused 
35 27 87 41 
839 647 1503 855 
1.35 1.13 2.1 1.1 
RBCs, Red blood cells. 
treated group. In our series, the mean units of red cells 
transfused in all patients (both EACA and control groups) 
with primary operations was only 0.84, a number less than 
that of both the control and aprotinin-treated groups 
receiving a primary CABG in Lemmer's eries. In a study 
of primary CABG operations reported by Daily and 
colleagues, 3 the number of patients receiving transfusions 
was significantly ess in the EACA-treated patients (4.8%) 
than in those in the control group (26.3%). 
Lemmer points out that we did not compare aprotinin 
against EACA. He is correct. We did not intend to do so. 
We only wished to ask whether EACA reduces blood loss 
when compared with a control series not receiving EACA. 
The only comparison of EACA with aprotinin made in 
our paper was of the cost of the two drugs. We did not 
claim that EACA more effectively reduces bleeding than 
does aprotinin, only that it does so less expensively. In 
fact, we are currently engaged in a Bayer-supported study 
of aprotinin to ascertain whether its documented reduc- 
tion of bleeding reduces transfusion costs and other 
intensive care unit costs (such as ventilator support) 
sutficiently to offset the high cost of the drug. 
We are embarrassed to realize that our paper contains 
an egregious numerical error--as Lemmer noticed and we 
did not. In the original manuscript, he cost of aprotinin 
was based on the (correct) volume use of the high-dose 
regimen: 200 ml before institution of cardiopulmonary 
bypass, 200 ml in the heart-lung pump prime, and an 
infusion rate during the operation of 50 ml/hr. When the 
final manuscript was submitted, the aprotinin dose was 
converted from milliliters to kallikrein inactivator units 
(kIU) and a tenfold error was introduced. None of the 
authors noticed the error. The correct doses are 2 × 106 
kIU before cardiopulmonary b pass, 2 × 106 kIU in the 
pump prime, and 0.5 × 106 kIU/hr infusion--not en 
times that dose, as was published. However, since the cost 
calculation was based on the volume dose used, the cost 
calculation of $785 per patient is correct as published, and 
the comparison with the $6.96 per-patient EACA cost 
remains rather striking. We apologize for the error, which, 
fortunately, did not affect the cost calculation in our 
paper. When we use aprotinin, we use the standard 
high-dose regimen as described above and in the package 
insert. 
Although Lemmer is critical of our conclusions, we 
suspect hat we both have nearly identical indications for 
the use of aprotinin. As does he, we use it only in 
operations expected to carry a high bleeding risk. We 
probably differ in that we do not use the drug routinely in 
redo operations because we do not consider those to carry 
a high bleeding risk. 
Thomas J. Vander Salm, MD 
Department of Surgery 
University of Massachusetts Medical Center 
55 Lake Ave., N. 
Worcester, MA 01655-0304 
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Twenty-three-year survival of a bovine pericardial 
bioprosthesis 
To the Editor." 
The letter by Trujillo and colleagues 1 concerning a 
19-year survival of a Hancock I porcine mitral bioprosthe- 
sis (Johnson & Johnson Cardiovascular, King of Prussia, 
Pa.) prompts us to report his 23-year survival of a bovine 
pericardial bioprosthesis in the aortic position. 
A male patient was noted to have a cardiac murmur on 
routine medical examination at the age of 11 years. In 
1972, at the age of 36 years, he was referred for treatment 
because of a 3-year history of dizziness, double vision, and 
progressive dyspnea on moderate xertion. A diagnosis of 
aortic stenosis was made. The patient was not evaluated 
by cardiac catheterization. On October 10, 1972, he 
underwent aortic valve replacement. A heavily calcified 
bicuspid aortic valve was excised and replaced with a 20 
mm standard-profil e Ionescu pericardial xenograft hat 
had been constructed by the surgical team at the Leeds 
General Infirmary. He made an uncomplicated postoper- 
